Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Clinical Trials Market Analysis by Phase, Study Design, Indication and Segment Forecasts, 2014 - 2025 - Research and Markets

Research and Markets
Posted on: 06 Oct 17

The "Clinical Trials Market Analysis by Phase (Phase I/II/III/IV), by Study Design (Interventional, Observational, Expanded Access), by Indication (Autoimmune, Pain management, Oncology, CNS condition, Diabetes, Obesity) and Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.

The global clinical trials market is expected to reach USD 65.2 billion by 2025.

Key drivers impacting the market growth are globalization of clinical trials, development of new treatments such as personalized medicine, augmenting evolution in technology, and boosting demand for CROs to conduct clinical trials.

Globalization of clinical trial has led to increase in investment in new product development in emerging countries thereby, having a positive impact on overall market. The availability of the vast array of services from drug discovery to post-marketing surveillance has further simplified the life for mid-size and small-scale pharmaceutical and biotechnological organizations by providing them the option to outsource what they think is beyond their core expertise. For instance, Pfizer currently has three CROs working with it to enhance its product portfolio and drive innovation. According to the partnership agreement with ICON in 2011, Pfizer would only preserve the scientific ownership for the trials and studies conducted by ICON, hence allowing the company to focus and further develop its capabilities in clinical trial designing.

Growing prevalence of disease and incidence of new disease is expected to give further boost to the clinical trial market. Worldwide population has varied disease profile with emerging countries having the most diverse disease profile. This is expected to boost the clinical trial of new or rare disease which otherwise would not have found any sponsors. More number of patients having a specific disease would act as a stimulus for biopharmaceutical companies to invest more in clinical trials for a disease segment.

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Clinical Trials Market Variables, Trends & Scope

Chapter 4 Clinical Trials Market: Phase Estimates & Trend Analysis

Chapter 5 Clinical Trials Market: Study Design Estimates & Trend Analysis

Chapter 6 Clinical Trials Market: Indication Estimates & Trend Analysis

Chapter 7 Clinical Trials Market: Regional Estimates & Trend Analysis, by Phase, Study Design, & Indication

Chapter 8 Competitive Landscape

  • Charles River Laboratory
  • Chiltern International Ltd.
  • ICON Plc
  • INC Research
  • PRA Health Sciences
  • Parexel International Corporation
  • Pharmaceutical Product Development, LLC
  • QuintilesIMS
  • SGS SA
  • Service Benchmarking
  • Wuxi AppTec Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 06/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.